Can't figure out the abbreviation of chemotherapy regimen?

1.

For non-small cell lung cancer ( NSCLC ) patients without driver mutations, chemotherapy remains the cornerstone of antitumor therapy

The classic first-line regimen for NSCLC is platinum-containing two drugs

For lung adenocarcinoma, pemetrexed + cisplatin is usually chosen

Also combined with platinum, paclitaxel liposome has comparable efficacy to paclitaxel, with better safety and tolerability, and lower peripheral neuritis

For patients with no disease progression, good physical status, and tolerable adverse reactions after 4-6 cycles of first-line treatment, single-agent maintenance therapy can be considered

Second-line chemotherapy was given to patients with a PS score of 0-2.

Etoposide in combination with cisplatin or carboplatin is the standard regimen for first-line therapy

• For SCLC that recurs more than 6 months after first-line treatment, the original first-line regimen can be used again for patients who are more sensitive to first-line treatment

  
  

• For patients whose recurrence time is less than 6 months, second-line drug switching should be considered; single drugs include: topotecan, irinotecan, gemcitabine, paclitaxel, docetaxel, temozolomide,

  
  

For SCLC that recurs more than 6 months after first-line treatment, the original first-line regimen can be used again for patients who are more sensitive to first-line treatment

For patients whose recurrence time is less than 6 months, second-line drug switching should be considered; single drugs include: topotecan, irinotecan, gemcitabine, paclitaxel, docetaxel, temozolomide,

2.

For patients with advanced breast cancer with tumor burden and no obvious symptoms, single-agent chemotherapy can be given priority;

Combination chemotherapy is preferred for symptomatic or visceral metastases requiring rapid remission
.
When choosing combination chemotherapy, it is necessary to weigh the efficacy and adverse effects
.

3.
Colorectal cancer

4.
Gastric cancer